Literature DB >> 14718593

Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.

Cassandra Y Baskfield1, Billy R Martin, Jenny L Wiley.   

Abstract

Mice devoid of CB1 cannabinoid receptors (CB1-/- mice) provide a unique opportunity to further investigate the role of CB1 receptors in exocannabinoid and endocannabinoid effects. CB1-/- mice (N = 18) and their wild-type littermates (CB1+/+ mice; N = 12) were placed in standard mouse operant chambers and trained to lever press under a fixed ratio 10 schedule of reinforcement. When stable lever press responding under the fixed ratio 10 schedule had been established, cannabinoids and noncannabinoids were administered to both groups. CB1+/+ mice acquired the lever press response more readily than CB1-/- mice. Delta(9)-Tetrahydrocannabinol (Delta(9)-THC) decreased lever press responding in CB1+/+ mice only, whereas methanandamide, a metabolically stable endocannabinoid analog, produced similar response rate decreases in both genotypic groups. Similar to Delta(9)-THC, another endocannabinoid analog, (R)-(20-cyano-16,16-dimethyl docosa-cis-5,8,11,14-tetraeno)-1'-hydroxy-2'-propylamine (O-1812), decreased responding in CB1+/+ mice, but not in CB1-/- mice. The CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A) blocked the effects of Delta(9)-THC, but not those of methanandamide. Because methanandamide binds poorly to CB2 receptors, these results suggest possible non-CB1, non-CB2 mechanisms of action for methanandamide-induced behavioral disruption of lever press responding. Ethanol and morphine elicited greater response decreases in CB1-/- mice than in CB1+/+ mice, suggesting a possible role of CB1 receptors in the rate disruptive effects of these drugs. In contrast, diazepam did not produce between group differences, suggesting that CB1 receptors are not involved in diazepam-induced disruption of lever press responding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718593     DOI: 10.1124/jpet.103.055376

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.

Authors:  Lance R McMahon; Brett C Ginsburg; R J Lamb
Journal:  Psychopharmacology (Berl)       Date:  2007-08-03       Impact factor: 4.530

3.  Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.

Authors:  Jenny L Wiley; D Matthew Walentiny; Robert E Vann; Cassandra Y Baskfield
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; V Kiran Vemuri; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2011-03-03       Impact factor: 4.530

5.  Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).

Authors:  Torbjörn U C Järbe; Richard J Lamb; Qian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

6.  Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.

Authors:  Torbjörn U C Järbe; Roger S Gifford; Alexandros Makriyannis
Journal:  Eur J Pharmacol       Date:  2010-09-18       Impact factor: 4.432

7.  Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.

Authors:  Torbjörn U C Järbe; Chen Li; Qian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2008-06-03       Impact factor: 4.530

Review 8.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

9.  Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

Authors:  Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2008-02-09       Impact factor: 4.530

Review 10.  In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.

Authors:  Andrea Giuffrida; Lance R McMahon
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-06-10       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.